Patents by Inventor Seishi Katsumata
Seishi Katsumata has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11215607Abstract: To provide a biomarker which is a metabolite included in a biological sample, and which can be collected in a noninvasive method and detected in a convenient analysis method, and which varies according to progression of pathological conditions of irritable bowel syndrome (IBS). Furthermore, such biomarkers are useful for determination of the presence or absence of morbidity of IBS, determination of severity of IBS, determination of types of IBS, determination of necessity of treatment of IBS, and confirmation of drug efficacy of an IBS therapeutic agent.Type: GrantFiled: February 18, 2015Date of Patent: January 4, 2022Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Shin Fukudo, Seishi Katsumata, Hideaki Tada, Akio Hayashi, Chie Murata
-
Patent number: 10675275Abstract: (1S)-2-acetyl-1-(4-chloro-2-methoxyphenyl)-5-fluoro-1,2,3,9-tetrahydrospiro[?-carboline-4,1?-cyclopropane] can significantly suppress a decrease of a pain threshold compared to well-known TSPO antagonists, and thus can be an excellent prophylactic and/or therapeutic agent for fibromyalgia, fibromyalgia-associated diseases, and fibromyalgia-associated symptoms.Type: GrantFiled: January 8, 2016Date of Patent: June 9, 2020Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Seishi Katsumata, Katsukuni Mitsui, Yuya Ezaki
-
Publication number: 20180169077Abstract: (1S)-2-acetyl-1-(4-chloro-2-methoxyphenyl)-5-fluoro-1,2,3,9-tetrahydrospiro[?-carboline-4,1?-cyclopropane] can significantly suppress a decrease of a pain threshold compared to well-known TSPO antagonists, and thus can be an excellent prophylactic and/or therapeutic agent for fibromyalgia, fibromyalgia-associated diseases, and fibromyalgia-associated symptoms.Type: ApplicationFiled: January 8, 2016Publication date: June 21, 2018Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Seishi KATSUMATA, Katsukuni MITSUI, Yuya EZAKI
-
Publication number: 20170119742Abstract: The present invention relates to a medicament for preventing and/or treating stress diseases, said medicament being characterized in that (1S)-2-acetyl-1-(4-chloro-2-methoxyphenyl)-5-fluoro-1,2,3,9-tetrahydrospiro[?-carboline-4,1?-cyclopropane] is administered at such a specific dose that a brain TSPO occupancy requiring for expressing the pharmacological effects of the medicament can be obtained.Type: ApplicationFiled: June 11, 2015Publication date: May 4, 2017Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Seishi KATSUMATA, Katsukuni MITSUI
-
Publication number: 20170059553Abstract: To provide a biomarker which is a metabolite included in a biological sample, and which can be collected in a noninvasive method and detected in a convenient analysis method, and which varies according to progression of pathological conditions of irritable bowel syndrome (IBS). Furthermore, such biomarkers are useful for determination of the presence or absence of morbidity of IBS, determination of severity of IBS, determination of types of IBS, determination of necessity of treatment of IBS, and confirmation of drug efficacy of an IBS therapeutic agent.Type: ApplicationFiled: February 18, 2015Publication date: March 2, 2017Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shin Fukudo, Seishi Katsumata, Hideaki Tada, Akio Hayashi, Chie Murata
-
Patent number: 7872133Abstract: The present invention relates to the compound represented by formula (I) A-X—Y—Z—B??(I) (wherein A is a cyclic group which may have a substituent(s); X is a single bond or a spacer; Y is a single bond or a spacer; Z is a single bond or a spacer; B is a hydrocarbon group which may have a substituent(s) or a cyclic group which may have a substituent(s)), a salt thereof, a solvate thereof or a prodrug thereof. The compound represented by formula (I), a salt thereof, a solvate thereof or a prodrug thereof is useful for preventive and/or therapeutic agent for a disease caused by stress.Type: GrantFiled: June 22, 2004Date of Patent: January 18, 2011Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Kazuyuki Ohmoto, Masashi Kato, Takeshi Matsushita, Seishi Katsumata, Junichiro Manako
-
Publication number: 20080249154Abstract: A compound represented by formula (I) (wherein ring A is a nitrogen-containing ring which may have a substituent(s), E is a binding bond or a spacer of which main chain has an atom number of 1-8, Q is a hydrogen atom, a hydrocarbon group which may have a substituent(s) or a cyclic group which may have a substituent(s).), a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof. Since the compounds of the present invention represented by formula (I), a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug thereof have the affinity to MBR, they are useful for the prevention and/or treatment for disease caused by stress.Type: ApplicationFiled: December 24, 2004Publication date: October 9, 2008Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Kazuyuki Ohmoto, Masashi Kato, Seishi Katsumata, Junichiro Manako
-
Patent number: 7368444Abstract: The present invention relates to the compound presented by formula (I) (wherein all symbols in formula (I) are the same mean as the description shown in the specification.), mitocondorial benzogeazepin receptor (MBR) antagonist comprising the compound, the preventive and/or treatment medicine against diseases caused by stress of which an active ingredient is the compound. Since the compound represented by formula (I) has MBR antagonistic activity, and controls the production of neurosteroid, it is useful as the preventive and/or treatment medicine against diseases caused by stress.Type: GrantFiled: February 13, 2003Date of Patent: May 6, 2008Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Takuya Seko, Seishi Katsumata, Masashi Kato, Jun-ichiro Manako, Kazuyuki Ohmoto
-
Publication number: 20070275990Abstract: The compound represented by formula (I) (wherein D and G are cyclic group which may have a substituent(s) or alkyl which may have a substituent(s), W and Y are a bond or a spacer of which main chain has an atom number of 1-4, ringA and ringB are heterocyclic ring which may have a substituent(s), containing at least one carbon atom and one nitrogen atom and the ringA and ringB share one spiro carbon atom), a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug thereof. Since the compounds represented by formula (I), a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug thereof have the affinity to MBR, they are useful for the prevention and/or treatment for disease caused by stress.Type: ApplicationFiled: November 12, 2004Publication date: November 29, 2007Inventors: Kazuyuki Ohmoto, Masashi Kato, Hiroshi Kohno, Seishi Katsumata, Junichiro Manako
-
Publication number: 20070099938Abstract: The compound represented by formula (I) (wherein ringA is cyclic group which may have a substituent(s), Q is alkyl which may have a substituent(s) or cyclic ring which may have a substituent(s), ringD is cyclic ring which may have a substituent(s), W is a single bond or a spacer of which main chain has an atom number of 1-4, Y is a spacer of which main chain has an atom number of 1-4.), a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug thereof Since the compounds represented by formula (I), a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug thereof have the affinity to MBR, they are useful for the prevention and/or treatment for disease caused by stress.Type: ApplicationFiled: October 22, 2004Publication date: May 3, 2007Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Kazuyuki Ohmoto, Masashi Kato, Seishi Katsumata, Junichiro Manako
-
Publication number: 20070027156Abstract: CRF antagonists comprising as an active ingredient, the compound of formula (I) wherein A ring is 5-6 membered mono-cyclic ring which may be substituted; B ring is 5-7 membered unsaturated mono-heterocyclic ring which may be contained another 1-2 of hetero atom(s) and substituted by another substituents; W1 and W2 is carbon atom or nitrogen atom; Z is NR3, oxygen atom, sulfur which may be oxidized or CR4R5; R1 is alkyl, alkenyl or alkynyl that may be substituted, amino which may be protected, hydroxyl which may be protected, S(O)nR6, COR7, or cyclic group which may be substituted; R2 is unsaturated cyclic group which may be substituted.Type: ApplicationFiled: September 8, 2004Publication date: February 1, 2007Inventors: Hisao Nakai, Tetsuji Saito, Tetsuo Obitsu, Chiaki Minamoto, Mayuki Yoshida, Akihiro Kishi, Seishi Katsumata, Hideo Katayama
-
Publication number: 20060154944Abstract: The present invention relates to the compound represented by formula (I) A—X—Y-Z-B??(I) (wherein A is a cyclic group which may have a substituent(s); X is a single bond or a spacer; Y is a single bond or a spacer; Z is a single bond or a spacer; B is a hydrocarbon group which may have a substituent(s) or a cyclic group which may have a substituent(s)), a salt thereof, a solvate thereof or a prodrug thereof. The compound represented by formula (I), a salt thereof, a solvate thereof or a prodrug thereof is useful for preventive and/or therapeutic agent for a disease caused by stress.Type: ApplicationFiled: June 22, 2004Publication date: July 13, 2006Inventors: Kazuyuki Ohmoto, Masashi Kato, Takeshi Matsushita, Seishi Katsumata, Junichiro Manako
-
Publication number: 20050101600Abstract: The present invention relates to the compound presented by formula (I) (wherein all symbols in formula (I) are the same mean as the description shown in the specification.), mitocondorial benzogeazepin receptor (MBR) antagonist comprising the compound, the preventive and/or treatment medicine against diseases caused by stress of which an active ingredient is the compound. Since the compound represented by formula (I) has MBR antagonistic activity, and controls the production of neurosteroid, it is useful as the preventive and/or treatment medicine against diseases caused by stress.Type: ApplicationFiled: February 13, 2003Publication date: May 12, 2005Inventors: Takuya Seko, Seishi Katsumata, Masashi Kato, Jun-ichiro Manako, Kazuyuki Ohmoto
-
Publication number: 20050009812Abstract: A pharmaceutical composition for the prophylaxis and/or treatment of diseases induced, exacerbated or reignited by stressors comprising the compound of formula (I) wherein all symbols have the same meanings as described in the specification, etc. as an active ingredient.Type: ApplicationFiled: October 4, 2002Publication date: January 13, 2005Inventors: Takuya Seko, Seishi Katsumata, Masashi Kato, Jun-ichiro Manako